• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
By KEVIN CURRAN Nov 06, 2018 | 02:13 PM EST
Stocks quotes in this article: LLY, ELAN, RHHBY, MRK, BMS, CELG, JNJ

Eli Lilly and Co. (LLY) could be making some splashes with big acquisitions in the fourth quarter.

The 142-year-old pharmaceutical company's war chest was built in large part by the IPO of its veterinary health unit, Elanco (ELAN) in September.

The company announced that the spinoff has left the company with 80.2% of Elanco, which it will actively work to divest within one year of the IPO. The spinoff netted Eli Lilly a handsome $4 billion, according to the company's SEC filings.

"We'll put that money (to use) against our capital priorities," Eli Lilly CFO Joshua Smiley told Reuters on Tuesday morning. "The Armo deal that we did earlier this year, we'll look to do more of those."

The company closed its acquisition of California-based ARMO BioSciences Inc in June for a reported $1.6 billion. The recent acquisition focuses on cancer treatments and immuno-oncology, an aspect of Lilly's offerings that have been ramping up as of late.

On Monday, the drug manufacturer announced a new partnership NextCure, Inc. to discover new cancer therapies and enter the market for cancer drugs, one of the more profitable sectors in medicine.

Roche Holdings'  (RHHBY) flagship offering to treat lymphoma, leukemia, and autoimmune disorders, Rituximab, generates over $7.1 billion per year alone for example.

Further expansion into the sector could make for interesting investments for traders interested in Lilly or looking to key in on potential M&A targets, which may even be hunted by companies aside from Lilly given underlying industry demand for deals.

To be sure, Smiley noted in his interview that large scales mergers in the industry are unlikely at this point, taking some blockbuster possibilities off the table.

The removal of mega-mergers from the range of possibility means that some of the most popular cancer drugs manufacturers like Merck (MRK) , Johnson & Johnson (JNJ) , Bristol Myers Squibb (BMS) , the aforementioned Roche and Celgene (CELG) will stand as serious challenges to Lilly's expansionary policy.

Company officials did not return requests for comment on possible acquisition targets and a timeline for actioning the prospective buyouts.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

Jim Cramer and the AAP team hold a position in Johnson & Johnson for their Action Alerts PLUS Charitable Trust Portfolio . Want to be alerted before Cramer buys or sells JNJ? Learn more now.

TAGS: Drug Approvals | Earnings | Investing | Stocks

More from Stocks

Let's Sift Through the Target and Cisco Carnage for Possible Trades

Bob Byrne
May 19, 2022 8:30 AM EDT

There isn't much to work with, but patient investors may find entry points after the implosion of both stocks.

Wingstop May Need More Napkins Before It Bottoms

Bruce Kamich
May 19, 2022 8:22 AM EDT

The shares peaked in September and have suffered a painful decline.

The Indexes Are No Longer Covering Up How Bad This Market Really Is

James "Rev Shark" DePorre
May 19, 2022 7:57 AM EDT

This bear market has been unusual because it has proceeded on a rolling basis.

No Place to Hide, Assessing the Beatdown, Dragon Breadth, Just Warming Up?

Stephen Guilfoyle
May 19, 2022 7:24 AM EDT

We ran, we ran all night and day... right back into U.S. Treasury securities, once again flattening the curve.

Hard-Hit Target Could Turn Into a Bullseye for Savvy Traders

Paul Price
May 19, 2022 7:00 AM EDT

Here's how to play this beleaguered retailer right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • 03:07 PM EDT PAUL PRICE

    Why Is Walmart Down Big Today?

    Besides its poor earnings report Walmart was way...
  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login